Clinical Research Directory

Inclusion Criteria: * Patients aged between 18-85 years presenting with non-STEMI according to current guidelines, who will be treated with PCI of the culprit and have at least one stenosis of \>50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator. * Non-IRA stenosis amenable for PCI treatment (operator's decision) * Signed informed consent Exclusion Criteria: * Left main disease (stenosis \> 50%) * Chronic total occlusion of a non-IRA * Indication for or previous coronary artery bypass grafting * Uncertain culprit lesion * Complicated IRA treatment, e.g. extravasation, permanent no re-flow after IRA treatment (TIMI flow 0-1) and inability to implant a stent * Known severe cardiac valve dysfunction that will require surgery or TAVI in the follow-up period. * Killip class III or IV during the completion of culprit lesion treatment. * Life expectancy of \< 1 year. * Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor or Heparin. * Gastrointestinal or genitourinary bleeding within the prior 3 months. * Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment. * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. * Pregnancy